Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — Shareholder Meeting (November 2024)
12 slides from Radiopharm Theranostics's shareholder meeting presentation, Nov 25, 2024
Slide 1: Company Presentation - Annual General Meeting
Company Presentation For personal use only Radiopharm Theranostics (ASX “RAD”) is a clinical stage radiopharmaceutical company developing Therapeutic and Imaging products using peptides, small molecules, nanobodies and antibodies. Annual General Meeting 25 November 2024
Slide 2: Notice & Disclaimer
Notice & Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN 647 877 889
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS 3 Innovative clinical stage molecules Highly differentiated Imaging agent (Pivalate) for Brain Mets - large disease area with high unmet need- For personal use only Potential first-in-class PD-L1 targeting radiopharmaceutical Potential best-in-class HER2 targeting radiopharmace
Slide 4: Company Pipeline
COMPANY PIPELINE TARGET & PROGRAM INDICATION Dx/Tx ISOTOPE PRECLINICAL PHASE I PHASE II NOTES MOLECULE Clinical For personal use only Phase 2a Phase 2b Short Chain IND approval received for Phase 2b in US (n=30) RAD 101 Fatty Acid BRAIN METS Imaging F18 (Small molecule) FPFV expected in Dec 2024 Pha
Slide 5: Targeting MoA: Short Fatty Acid Chains - RAD 101
For personal use only Targeting MoA: SHORT FATTY ACID CHAINS Imaging for BRAIN METASTASIS Molecule: RAD 101
Slide 6: Upcoming Milestones
For personal use only UPCOMING MILESTONES TARGET & 1ST HALF 2ND HALF 1ST HALF 2ND HALF 1ST HALF PROGRAM INDICATION Dx/Tx ISOTOPE MOLECULE 2024 2024 2025 2025 2026 IND Approval Short Phase 2b 10/30 Phase 2 Chain BRAIN received RAD101 Imaging F18 patients’ data Top Line data Fatty Acid METS to be rele
Slide 7: Targeting MoA: PD-L1 - RAD204
For personal use only Targeting MoA: PDL1 Molecule: RAD 204 Therapeutic for NON-SMALL CELL LUNG CANCER 7
Slide 8: RAD204 - Upcoming Milestones
RAD 204 – UPCOMING MILESTONES TARGET & 1ST HALF 2ND HALF 1ST HALF 2ND HALF 1ST HALF PROGRAM INDICATION Dx/Tx ISOTOPE MOLECULE 2024 2024 2025 2025 2026 For personal use only Ethics First Patient Approval treated at received Wollongong PD-L1 NON-SMALL Hospital 2 Cohorts Phase 1 RAD204 CELL LUNG Therap
Slide 9: Targeting MoA: HER2 - RAD202
For personal use only Targeting MoA: HER2 Molecule: RAD 202 Therapeutic for BREAST AND GASTRIC CANCER 9
Slide 10: RAD202 - Upcoming Milestones
RAD 202 – UPCOMING MILESTONES For personal use only TARGET & 1ST HALF 2ND HALF 1ST HALF 2ND HALF 1ST HALF PROGRAM INDICATION Dx/Tx ISOTOPE MOLECULE 2024 2024 2025 2025 2026 Ethics HER2 Submission 2 Cohorts Phase 1 BREAST First Patient RAD202 & GASTRIC Therapy Lu177 dosed completed Top Line data (Nan
Slide 11: Corporate Snapshot
CORPORATE SNAPSHOT Top 20 Shareholders 2024, Oct 29th JP Morgan (incl. Point72) 175.096.000 Shareholders: Deutsche Bank 157.420.000 64% Institutions + 10% Board Lantheus 149.625.000 Stock Code: RAD Paul Hopper 149.221.000 For personal use only Regal Funds 142.140.000 12-month trading range: Octagon
Slide 12: Contacts
Contacts For personal use only Riccardo Canevari Paul Hopper CEO & Managing Director Executive Chairman T +1 862 309 0293 T +61 406 671 515 E rc@radiopharmtheranostic.com E paulhopper@lifescienceportfolio.com W www.radiopharmtheranostics.com W www.radiopharmtheranostics.com 12
Radiopharm Theranostics — Shareholder Meeting (November 2024) on 6ix